Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2010 3
2011 1
2012 2
2013 6
2014 9
2015 7
2016 8
2017 2
2018 2
2019 3
2020 2
2022 5
2023 14
2024 7
2025 13
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Results by year

Filters applied: . Clear all
Quoted phrases not found in phrase index: "ERAS4OLT.org tanaka T", "Transplant Proc. 2013 2288-94", "tomohiro tanaka transplant proc", "tomohiro tanaka toronto", "tomohiro tanaka kokudo", "tomohiro tanaka namiki izumi", "tomohiro tanaka iowa"
Page 1
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Müller HL, Roth CL; TRANSCEND Trial Group. Miller JL, et al. Among authors: tanaka t. N Engl J Med. 2026 Jul 9;395(2):138-150. doi: 10.1056/NEJMoa2512275. N Engl J Med. 2026. PMID: 42418774 Clinical Trial.
Incorporating Model for End-stage Liver Disease Trajectories into Liver Allocation.
Tanaka T, Lai JC, Axelrod D. Tanaka T, et al. Transplantation. 2026 Jun 9. doi: 10.1097/TP.0000000000005771. Online ahead of print. Transplantation. 2026. PMID: 42260591
BACKGROUND: Liver transplant (LT) allocation prioritizes candidates by current Model for End-stage Liver Disease (MELD) score, without accounting for disease trajectory. ...
BACKGROUND: Liver transplant (LT) allocation prioritizes candidates by current Model for End-stage Liver Disease (MELD) score, withou …
Bilirubin-Driven Phenotype Identifies Higher Mortality Risk in Severe Alcohol-Associated Hepatitis.
Ayele TT, Tanaka T. Ayele TT, et al. Among authors: tanaka t. Gastro Hep Adv. 2026 Apr 24;5(7):100982. doi: 10.1016/j.gastha.2026.100982. eCollection 2026. Gastro Hep Adv. 2026. PMID: 42222299 Free PMC article.
CONCLUSION: A bilirubin-dominant phenotype in severe AH was associated with significantly higher 90-day mortality, highlighting disease heterogeneity and suggesting potential value for risk stratification and for guiding future research on individualized care and optimal timing o …
CONCLUSION: A bilirubin-dominant phenotype in severe AH was associated with significantly higher 90-day mortality, highlighting disease hete …
Impact of Model for End-stage Liver Disease Cutoffs on Liver Transplant Access in the United States: A Regression Discontinuity Design.
Tanaka T, Jones MP, Wehby G, Axelrod D. Tanaka T, et al. Transplantation. 2026 May 1;110(5):e1027-e1034. doi: 10.1097/TP.0000000000005650. Epub 2026 Feb 2. Transplantation. 2026. PMID: 41628055
BACKGROUND: Since Share-35 and continuing under the Acuity Circle (AC) policy, US liver transplant (LT) allocation has relied on Model for End-Stage Liver Disease (MELD) thresholds that may distort fair and seamless access. ...Regression discontinuity analysis using Poisso …
BACKGROUND: Since Share-35 and continuing under the Acuity Circle (AC) policy, US liver transplant (LT) allocation has relied on Mode …
Hepatitis C Virus (HCV) Recurrence and Death After Viral Clearance in an HCV-Viremic Donor to HCV-Negative Kidney Recipient.
He S, Tanaka T, Kim SH, Thomsen D, Katz DA, Thomas CP, Rastogi P, Aziz H, Reed AI. He S, et al. Among authors: tanaka t. Kidney Med. 2025 Oct 10;7(12):101139. doi: 10.1016/j.xkme.2025.101139. eCollection 2025 Dec. Kidney Med. 2025. PMID: 41333095 Free PMC article.
A 52-year-old man with type 2 diabetes underwent a deceased donor HCV NAT+/- kidney transplant. Postoperatively, the allograft function gradually improved without necessitating dialysis. ...Fatal recurrence is rare in HCV NAT+/- kidney transplant recipients after co …
A 52-year-old man with type 2 diabetes underwent a deceased donor HCV NAT+/- kidney transplant. Postoperatively, the allograft functi …
Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access.
Tanaka T, Shane DM, Lai JC. Tanaka T, et al. Hepatology. 2026 Jul 1;84(1):106-116. doi: 10.1097/HEP.0000000000001581. Epub 2025 Oct 16. Hepatology. 2026. PMID: 41100798
BACKGROUND: The July 2023 implementation of MELD3.0 aimed to address longstanding sex disparities in liver transplant access. However, its impact has been understudied. METHODS: We analyzed US transplant registry data (February 4, 2020-September 30, 2024) among adul …
BACKGROUND: The July 2023 implementation of MELD3.0 aimed to address longstanding sex disparities in liver transplant access. However …
85 results